180 related articles for article (PubMed ID: 29967609)
21. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
Keyel ME; Reynolds CP
Biologics; 2019; 13():1-12. PubMed ID: 30613134
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN
MAbs; 2016; 8(3):604-16. PubMed ID: 26785755
[TBL] [Abstract][Full Text] [Related]
23. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
26. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR; Villablanca JG; London WB; Gerbing RB; Haas-Kogan D; Adkins ES; Attiyeh EF; Maris JM; Seeger RC; Reynolds CP; Matthay KK;
Pediatr Blood Cancer; 2009 Jan; 52(1):44-50. PubMed ID: 18937318
[TBL] [Abstract][Full Text] [Related]
27. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
[TBL] [Abstract][Full Text] [Related]
28. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
[TBL] [Abstract][Full Text] [Related]
29. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
31. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
32. Dinutuximab: A Review in High-Risk Neuroblastoma.
Hoy SM
Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
[TBL] [Abstract][Full Text] [Related]
33. Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Troschke-Meurer S; Siebert N; Marx M; Zumpe M; Ehlert K; Mutschlechner O; Loibner H; Ladenstein R; Lode HN
Oncoimmunology; 2019; 8(12):1661194. PubMed ID: 31741754
[TBL] [Abstract][Full Text] [Related]
34. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
35. Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma.
Qayed M; Chiang KY; Ricketts R; Alazraki A; Tahvildari A; Haight A; George B; Esiashvili N; Katzenstein HM
Pediatr Blood Cancer; 2012 Mar; 58(3):448-52. PubMed ID: 21538822
[TBL] [Abstract][Full Text] [Related]
36. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
37. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
Marachelian A; Desai A; Balis F; Katzenstein H; Qayed M; Armstrong M; Neville KA; Cohn SL; Bush M; Gunawan R; Lim AP; Smith MA; Smith LM
Cancer Chemother Pharmacol; 2016 Feb; 77(2):405-12. PubMed ID: 26791869
[TBL] [Abstract][Full Text] [Related]
39. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Siebert N; Troschke-Meurer S; Marx M; Zumpe M; Ehlert K; Gray J; Garaventa A; Manzitti C; Ash S; Klingebiel T; Beck J; Castel V; Valteau-Couanet D; Loibner H; Ladenstein R; Lode HN
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30336605
[TBL] [Abstract][Full Text] [Related]
40. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
